Related Experiment Video
Updated: Dec 14, 2025
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review
Elmira Mohtashami1, Negar Shafaei-Bajestani2, Hamid Mollazadeh3,4
1Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract:
Glioblastoma multiforme (GBM), as the most lethal brain tumor, continues to be incurable. Considering the high mortality rate of GBM, it is crucial to develop new treatment approaches. Conventional therapies, including maximal surgical resection, radiation therapy, and chemotherapy (typically temozolomide), have not led to significant changes in the survival rates of GBM patients. However, emerging modalities, such as the use of tyrosine kinase inhibitors, mTOR inhibitors, NF-κB modulators, nitrosoureas, and immunotherapeutic agents have shown promising in improving GBM outcomes. In this context, we reviewed the current status of GBM treatment, the efficacy of existing standard therapies in improving disease outcomes, and future therapeutic directions.
Insights
Glioblastoma multiforme (GBM) remains incurable despite standard treatments. Emerging therapies like tyrosine kinase inhibitors and immunotherapy offer promising new avenues for improving patient outcomes in this lethal brain tumor.
Area of Science:
- Neuro-oncology
- Cancer Therapeutics
Background:
- Glioblastoma multiforme (GBM) is the most lethal primary brain tumor with a poor prognosis.
- Current standard treatments (surgery, radiation, temozolomide chemotherapy) have limited impact on survival rates.
Purpose of the Study:
- To review the current treatment landscape for GBM.
- To evaluate the efficacy of established therapies.
- To explore novel therapeutic strategies for glioblastoma.
Main Methods:
- Literature review of glioblastoma multiforme treatment modalities.
- Analysis of conventional and emerging therapeutic approaches.
- Synthesis of data on treatment efficacy and future directions.
Main Results:
- Standard GBM therapies offer limited survival benefits.
- Emerging treatments including tyrosine kinase inhibitors, mTOR inhibitors, NF-κB modulators, nitrosoureas, and immunotherapy show potential.
- Further research into novel agents is warranted.
Conclusions:
- Glioblastoma multiforme treatment requires innovative approaches beyond current standards.
- Targeted therapies and immunotherapies represent promising future directions for GBM management.
- Continued investigation into novel treatment modalities is crucial for improving GBM patient outcomes.
